Navigation Links
Gemzar the New Drug for Recurrent Ovarian Cancer

The FDA has approved Gemzar for the treatment of recurrent ovarian cancer ignoring the advice of the FDA panel.//

It said that Gemzar in combination with carboplatin (chemotherapy) is very effective for women with advanced ovarian cancer. The drug Gemzar also known by its generic name gemcitabine and was approved after the company provided with additional information to the FDA. According to the statistics of the American Cancer Society about 22,000 women are diagnosed with the disease and 16,000 women die each year. The problem with ovarian cancer is that the tumor tends to recur, making the treatment difficult and resulting in low survival rates.

Gemzar is already approved in the US for lung, pancreatic and breast cancers. In the clinical trails it was found that ovarian cancer patients taking Gemzar with carboplatin had increased progression-free survival rates than patients taking carboplatin alone. The FDA advisory panel voted against recommending the drug when the panel members were concerned that patients in the trial did not survive longer than those taking carboplatin alone. But the company replied that their aim is to prevent the cancer from worsening and not to help patients live longer. The treatment with Gemzar costs about $12,600 which does not increase the longevity of the patient but allows them to have less frequent chemotherapy.


'"/>




Page: 1

Related medicine news :

1. Estrogen Does Not Prevent Recurrent Strokes
2. Radiation Therapy An Effective Solution For Recurrent Prostate Cancer
3. Prevention Of Recurrent Leg Ulcers
4. Measuring Urinary Protein Helps In Detecting Recurrent Bladder Cancer
5. Sertraline Can Prevent Recurrent Depressive Episodes In Diabetics
6. Angola Warned of Recurrent Cholera Outbreaks
7. Recurrent Stroke Risk is Minimized by Statin
8. Blood Markers Predict Risk for Recurrent Stroke and Mortality
9. Targeted Compound Helps Recurrent Prostate Cancer Patients
10. Ancient Indian Herb May Prove Cure For Recurrent UTI
11. Ovarian cancer in relationship with Hormone therapy
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... ... 28, 2017 , ... Resoundant, Inc., the developer of ... Healthineers annual customer education symposium, a world-class learning conference that offers educational content ... - 31, 2017 at the Atlanta Marriott Marquis in Atlanta, Georgia. , Innovations ...
(Date:3/28/2017)... ... March 29, 2017 , ... The Thyroid ... Isabella Wentz, Pharm.D., FASCP. The program was recently launched on March 1, and ... regarding thyroid function. , Dr. Izabella Wentz is a licensed pharmacist and ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... share of all holidays (IBT World Travel Trends Report). As travelers visit both ... a range in temperatures, and prolonged sun exposure. In response, the outdoor industry ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... the science and clinical practice of radiosurgery, announced today the publication of ... observational registry established to standardize data collection from patients treated with stereotactic ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... Alert Sentry ... of MPERS (Mobile Personal Emergency Response Systems), the iSAFE and the iSAFE Plus. These ... market. The first of their kind, the iSAFE and iSAFE Plus offer direct GPS ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... REDWOOD CITY, Calif. , March 28, 2017 ... pharmaceutical company focused on the development and commercialization ... acute pain, announced that the European Medicines Agency ... (sufentanil sublingual tablet, 30 mcg) Marketing Authorisation Application ... review of the MAA is underway. The MAA ...
(Date:3/28/2017)... 28, 2017 RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Japan Patent Office (JPO) for the composition of ... (CTGF) for the treatment or prevention of fibrotic ... and proliferative retinopathy (Japanese Patent #: 6060071).  This ...
(Date:3/28/2017)... , March 28, 2017 ... to reach USD 8.0 billion by 2025, according to ... increasing incidence of infectious diseases and cancer is expected ... in disease diagnosis over the coming years. In addition, ... of autologous and allogenic stem cell therapy, due to ...
Breaking Medicine Technology: